In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble
Zydus Lifesciences Ltd Q4FY25; 0% fall in Profits
Categories
Generic drug
Torrent Pharmaceuticals Ltd Q4FY25; 11% rise in Profits
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Lupin Ltd Q1FY25; 78% rise in Profits
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations,
Piramal Pharma Ltd Q1FY25; 12% rise in Revenue
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and
Unichem Laboratories Ltd Q4FY24; 7% rise in Revenue
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. Financial Results: Unichem Laboratories Ltd reported Revenues
Torrent Pharmaceuticals Ltd Q4FY24; 56% rise in Profits
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Torrent Pharmaceuticals Ltd Q3FY24; 52% rise in Profits
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Pfizer Ltd Q3FY24; 14% fall in Profits
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also
Marksans Pharma Ltd Q3FY24; 34% rise in Profits
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q3FY24 of
Unichem Laboratories Ltd Q3FY24; 44% rise in Revenue
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. Financial Results: Unichem Laboratories Ltd reported Revenues
Sun Pharmaceuticals Industries Ltd Q3FY24; 17% rise in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
Pfizer Ltd Q2FY24; 52% fall in Profits
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also
Sanofi India Ltd Q2FY24; 16% rise in Profits
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q2FY24
Strides Pharma Science Ltd Q2FY24; 11% rise in Revenue
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in
Torrent Pharmaceuticals Ltd Q1FY24; 7% rise in Profits
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Torrent Pharmaceuticals Ltd Q4FY23 revenue grows by 17%
Torrent Pharmaceuticals Ltd reported Total revenue for Q4 FY23 of ₹2,452 Crore, up from ₹ Crore year on year depicting a growth
Dr. Reddy’s Laboratories: One Of The Major Player In Generic Segment
“We are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The
Torrent pharma Q3FY23 net profit rises by 14 percent
Torrent Pharma reported that its consolidated net profit increased by 14 per cent to INR 283 crore in the third quarter ended
Wockhardt posted a net loss of INR 102 Crores in Q3FY23
Drugmaker Wockhardt posted a consolidated loss of ₹102 crore for the three months ended December 31, 2022. The company posted a profit
Zydus lifescience net profit soars by 23% in Q3FY23
Zydus Lifesciences Ltd reported a 23 per cent rise in consolidated net profit at INR 631 crore for the third quarter ended
Zydus Lifesciences Q3FY23 net profit rises by 23%; Revenue soars 20%
Zydus Lifesciences Ltd reported a 23 per cent rise in consolidated net profit at INR 631 crore for the third quarter ended